About the Company
We do not have any company description for NeuroPace Inc at the moment.
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & Apparatus
Employees
212
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on NeuroPace Inc
NeuroPace, Inc. (NASDAQ:NPCE) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 12, 2025 NeuroPace, Inc. misses on earnings expectations. Reported EPS is $-0.26 EPS, ...
Earnings To Watch: NeuroPace Inc (NPCE) Reports Q2 2025 Result
NeuroPace Inc (NASDAQ:NPCE) is set to release its Q2 2025 earnings on Aug 12, 2025. The consensus estimate for Q2 2025 ...
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates
NeuroPace, Inc. (NPCE) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.26 per share a year ago. These figures ...
NeuroPace Inc (NPCE) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...
NeuroPace Inc (NPCE) reports a 22% revenue growth and raises full-year guidance amidst promising trial data and strategic financial moves.
NeuroPace to Showcase the RNS System at the 2024 American Epilepsy ...
MOUNTAIN VIEW, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- December 4, 2024 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with ...
NeuroPace Announces FDA Submission of Three-Year Data from Post ...
Join for Free » NeuroPace Announces FDA Submission of Three-Year Data from Post-Approval Study of the RNS System in Focal Epilepsy Nov. 04, 2024 4:05 PM ET NeuroPace, Inc. (NPCE) ...
NeuroPace, Inc. to Present at Leerink Partners 2025 Global ... - Nasdaq
NeuroPace will present at the Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, in Miami, FL. Quiver AI Summary NeuroPace, Inc., a medical device company dedicated to improving ...
Bear of the Day: NeuroPace (NPCE) - Nasdaq
NeuroPace NPCE is a $200 million commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from epilepsy. NeuroPace Inc. is ...
NeuroPace Announces Pricing of Public Offering of $65 Million of
MOUNTAIN VIEW, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) today announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a ...
NeuroPace Secures Up to $75 Million in Debt Financing
Additional detail regarding the foregoing financing is set forth in NeuroPace’s Current Report on Form 8-K, filed today with the U.S. Securities and Exchange Commission. About NeuroPace, Inc.
NeuroPace, Inc. (NPCE) Q3 2023 Earnings Call Transcript
NeuroPace, Inc. (NASDAQ:NPCE) Q3 2023 Earnings Conference Call November 6, 2023 4:30 PM ETCompany ParticipantsIrina Ridley - Chief Legal Officer and Head of ...
Accelmed Partners Takes Activist Position in NPCE / Neuropace After Q3 ...
Fintel reports that Accelmed Partners II L.P. has filed a 13D form with the SEC disclosing ownership of 4,042,657 shares of Neuropace, Inc. (NPCE). This represents 16.2% of the company.
Similar Companies
Loading the latest forecasts...